Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099502 · ClinicalTrials.gov registry record · Phase 3
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,244
- Enrollment target
NCT00099502 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 2,244 participants.
The verdict
NCT00099502, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,244 participants
- Enrollment target
Study Summary
The purpose of this study is to determine * whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms * whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and more efficacious than treatment with Copaxone (Glatiramer Acetate) 20 mg
Interventions
- DRUG Copaxone
- DRUG Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,244 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099502
The ClinicalTrials.gov registry entry for NCT00099502 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,244 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Copaxone is the first listed.
NCT00099502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099502 about?
NCT00099502 is a clinical study titled "BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients". The purpose of this study is to determine * whether treatment with Betaferon / Betaseron (interferon beta-1b) 500 micrograms safe, tolerable and more efficacious than treatment with interferon beta-1b 250 micrograms * whether treatment with Betaferon / Betaseron (interferon beta-1b) tolerable and m...
What is the current status of trial NCT00099502?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,244 participants. The study started on 2003-11. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00099502?
The interventions under investigation include: Copaxone (DRUG), Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) (DRUG).
Who is sponsoring clinical trial NCT00099502?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.